Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2003-09-24

Last Posted Date: 2014-05-22

Lead Sponsor: University of Southern California

Target Recruit Count: 35

Registration Number: NCT00003449

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: dexamethasone
Drug: semaxanib

First Posted Date: 2003-08-29

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 36

Registration Number: NCT00006002

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 15 locations

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Biological: recombinant interferon alfa
Drug: doxorubicin hydrochloride
Drug: carmustine
Drug: melphalan
Drug: cyclophosphamide
Drug: prednisone
Drug: dexamethasone
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic bone marrow transplantation
Procedure: autologous bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2003-08-11

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 899

Registration Number: NCT00002548

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
New England Medical Center Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 31 locations

Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-07-30

Last Posted Date: 2020-04-09

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 77

Registration Number: NCT00014209

Locations: 🇨🇦
Credit Valley Hospital, Mississauga, Ontario, Canada
🇨🇦
Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 10 locations

Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-07-28

Last Posted Date: 2015-04-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00006240

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Mount Sinai Medical Center, NY, New York, New York, United States
🇺🇸
National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States

and more 1 locations

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-07-09

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00002878

Locations: 🇺🇸
CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada

and more 37 locations

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Phase 3

Completed

Conditions: Plasma Cell Neoplasm
Multiple Myeloma

Interventions: Drug: dexamethasone
Other: placebo
Drug: lenalidomide

First Posted Date: 2003-07-09

Last Posted Date: 2015-03-25

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 198

Registration Number: NCT00064038

Locations: 🇺🇸
William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
🇺🇸
Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Phase 2

Completed

Conditions: Multiple Myeloma
Plasma Cell Myeloma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: dexamethasone
Drug: melphalan
Drug: thalidomide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-07-09

Last Posted Date: 2018-08-09

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 104

Registration Number: NCT00064337

Locations: 🇺🇸
Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States
🇺🇸
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸
St. Peter's Hospital, Helena, Montana, United States

and more 31 locations

Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 1

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-06-06

Last Posted Date: 2015-03-30

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 22

Registration Number: NCT00010231

Locations: 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Undifferentiated Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
L1 Adult Acute Lymphoblastic Leukemia
L1 Childhood Acute Lymphoblastic Leukemia
L2 Adult Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia

Interventions: Drug: allopurinol
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: vincristine sulfate
Drug: dexamethasone
Drug: asparaginase
Biological: filgrastim
Drug: imatinib mesylate
Drug: methotrexate
Drug: cytarabine
Drug: trimethoprim-sulfamethoxazole
Drug: mercaptopurine
Drug: leucovorin calcium
Biological: alemtuzumab
Drug: acyclovir
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-06-06

Last Posted Date: 2022-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 302

Registration Number: NCT00061945

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy